Bupivacaine and Epinephrine Injection Study

Launched by AMIN JAVER · Jun 7, 2024

Keywords

ClinConnect Summary

The Bupivacaine and Epinephrine Injection Study is investigating how a specific combination of medications—bupivacaine (a local anesthetic) and epinephrine (a drug that helps reduce bleeding)—affects the visibility for surgeons during endoscopic sinus surgery (ESS). This surgery is often performed to clear blocked sinuses and improve breathing. The study aims to find out if using this drug combination makes a significant difference in helping surgeons see better compared to not using any injections at all.

To participate in this trial, you need to be at least 19 years old and scheduled for your first ESS, which may include procedures like septoplasty (correcting the nasal septum). However, some people may not be eligible, including those with certain medical conditions like cystic fibrosis or bleeding disorders, and those who have had previous sinus surgery. If you join the study, you’ll receive information about what to expect during the process, including the potential risks and benefits of the injection. Please note that the trial is not yet recruiting participants, but it’s important to stay informed if you think you might be eligible.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 19 years or older
• • Scheduled for primary ESS (including septoplasty)
• Exclusion Criteria:
• • Cystic fibrosis
• • Systemic vasculitis or any bleeding disorders
• • Known or suspected hypersensitivity to bupivacaine or epinephrine
• • Previous sinus surgery
• • Inhaled drug use (i.e., cocaine) in the preceding 6 months
• • Nasal tumors
• • Patients on antiarrhythmics.
• • Patients with history of severe liver illness.
• • Patients identified as high-risk for complications during preoperative assessment with the anesthesiologist (e.g. untreated hypertension, ischemic heart disease, cerebral vascular insufficiency, heart block, peripheral vascular disorder, uncontrolled hyperthyroidism and diabetes)